Latest Stocks: Roth Capital Reiterates $5.00 Price Target for BioDelivery Sciences International, Inc. (BDSI)

Latest Stocks: Roth Capital Reiterates $5.00 Price Target for BioDelivery Sciences International, Inc. (BDSI)

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has been assigned a $5.00 price objective by investment analysts at Roth Capital in a report issued on Tuesday, May 16th. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Roth Capital’s price target suggests a potential upside of 122.22% from the company’s current price.

BDSI has been the topic of a number of other reports. Cantor Fitzgerald set a $3.00 target price on BioDelivery Sciences International and gave the stock a “hold” rating in a research report on Tuesday, January 17th. Zacks Investment Research cut shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research note on Wednesday, February 8th. FBR & Co set a $5.00 price target on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Thursday, February 2nd. Finally, Janney Montgomery Scott restated a “buy” rating and set a $3.00 price target on shares of BioDelivery Sciences International in a research note on Monday, March 20th. Three analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $3.71.

BioDelivery Sciences International (BDSI) opened at 2.25 on Tuesday. BioDelivery Sciences International has a 52 week low of $1.50 and a 52 week high of $3.10. The stock’s 50 day moving average price is $1.97 and its 200 day moving average price is $1.90. The firm’s market capitalization is $124.48 million.

In related news, CEO Mark A. Sirgo sold 110,895 shares of the company’s stock in a transaction on Friday, March 31st. The shares were sold at an average price of $1.90, for a total value of $210,700.50. Following the completion of the transaction, the chief executive officer now directly owns 1,670,157 shares of the company’s stock, valued at approximately $3,173,298.30. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 112,345 shares of company stock valued at $213,456 in the last three months. 9.00% of the stock is owned by company insiders. A number of institutional investors have recently made changes to their positions in the company. Broadfin Capital LLC raised its position in shares of BioDelivery Sciences International by 4.0% in the fourth quarter. Broadfin Capital LLC now owns 5,398,794 shares of the specialty pharmaceutical company’s stock worth $9,448,000 after buying an additional 210,000 shares during the last quarter. Stonepine Capital Management LLC boosted its stake in shares of BioDelivery Sciences International by 9.4% in the first quarter. Stonepine Capital Management LLC now owns 2,844,820 shares of the specialty pharmaceutical company’s stock valued at $5,405,000 after buying an additional 244,109 shares during the period. Vanguard Group Inc. boosted its stake in shares of BioDelivery Sciences International by 2.0% in the first quarter. Vanguard Group Inc. now owns 2,271,519 shares of the specialty pharmaceutical company’s stock valued at $4,315,000 after buying an additional 44,036 shares during the period. Grandeur Peak Global Advisors LLC boosted its stake in shares of BioDelivery Sciences International by 5.9% in the first quarter. Grandeur Peak Global Advisors LLC now owns 1,007,006 shares of the specialty pharmaceutical company’s stock valued at $1,913,000 after buying an additional 56,550 shares during the period. Finally, Blair William & Co. IL boosted its stake in shares of BioDelivery Sciences International by 37.6% in the first quarter. Blair William & Co. IL now owns 693,181 shares of the specialty pharmaceutical company’s stock valued at $1,386,000 after buying an additional 189,484 shares during the period. 53.57% of the stock is owned by hedge funds and other institutional investors.

Receive News & Ratings for BioDelivery Sciences International Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment